| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
37,720,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC™ targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
7,222 |
27,098 |
33,468 |
53,826 |
| Total Sell Value |
$171,618 |
$519,450 |
$663,415 |
$1,227,017 |
| Total People Sold |
7 |
7 |
7 |
9 |
| Total Sell Transactions |
7 |
13 |
25 |
38 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lee Kevin |
Chief Executive Officer |
• • – |
2021-05-03 |
4 |
OE |
$14.00 |
$47,474 |
D/D |
3,391 |
258,125 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-30 |
4 |
AS |
$29.89 |
$935,204 |
D/D |
(30,406) |
254,734 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-30 |
4 |
OE |
$14.00 |
$425,684 |
D/D |
30,406 |
285,140 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-29 |
4 |
AS |
$30.35 |
$183,612 |
D/D |
(6,018) |
254,734 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-29 |
4 |
OE |
$14.00 |
$84,252 |
D/D |
6,018 |
260,752 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-28 |
4 |
AS |
$30.43 |
$699,172 |
D/D |
(22,495) |
254,734 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-28 |
4 |
OE |
$14.00 |
$314,930 |
D/D |
22,495 |
277,229 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-27 |
4 |
AS |
$30.66 |
$203,728 |
D/D |
(6,636) |
254,734 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-27 |
4 |
OE |
$14.00 |
$92,904 |
D/D |
6,636 |
261,370 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-26 |
4 |
AS |
$30.63 |
$582,144 |
D/D |
(18,611) |
254,734 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-04-26 |
4 |
OE |
$14.00 |
$203,630 |
D/D |
14,545 |
273,345 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-04-08 |
4 |
AS |
$31.40 |
$787,588 |
D/D |
(24,838) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-04-08 |
4 |
OE |
$8.74 |
$217,084 |
D/D |
24,838 |
24,838 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-04-05 |
4 |
AS |
$31.07 |
$5,033 |
D/D |
(162) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-04-05 |
4 |
OE |
$8.83 |
$1,430 |
D/D |
162 |
162 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-31 |
4 |
AS |
$30.00 |
$300,000 |
D/D |
(10,000) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-31 |
4 |
OE |
$8.78 |
$87,800 |
D/D |
10,000 |
10,000 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2021-03-31 |
4 |
AS |
$30.00 |
$300,000 |
D/D |
(10,000) |
28,321 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-17 |
4 |
S |
$29.00 |
$225,736 |
D/D |
(7,784) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-17 |
4 |
OE |
$8.85 |
$68,888 |
D/D |
7,784 |
7,784 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2021-03-15 |
4 |
AS |
$28.00 |
$6,076 |
D/D |
(217) |
38,321 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-12 |
4 |
S |
$29.00 |
$64,264 |
D/D |
(2,216) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-12 |
4 |
OE |
$8.86 |
$19,634 |
D/D |
2,216 |
2,216 |
|
- |
|
| Keen Nicholas |
Chief Scientific Officer |
• – – |
2021-03-12 |
4 |
AS |
$28.48 |
$278,767 |
D/D |
(9,783) |
38,538 |
|
- |
|
| Lee Kevin |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
AS |
$31.00 |
$3,100 |
D/D |
(100) |
258,800 |
|
- |
|
226 Records found
|
|
Page 7 of 10 |
|
|
